Top

Gepubliceerd in:

01-12-2006 | Artikelen

Cystic fibrosis; een vergrijzend ziektebeeld?

Auteurs: C. K. van der Ent, I. Drubbel, A. M. M. de Vrankrijker, H. G. M. Arets, H. G. M. Heijerman

Gepubliceerd in: Tijdschrift voor Kindergeneeskunde | Uitgave 6/2006

Summary

Cystic fibrosis (cf) is the most frequent occurring hereditary lethal disease in Western countries. Improvement of treatment strategies in cf have resulted in major improvements of life expectancy. Several decades ago cf was treated exclusively by paediatricians, nowadays the median life expectancy is between 30 and 35 years. Many patients are treated by pulmonologists and other medical specialists for adults. The improved survival has led to the emergence of new complications of the disease, like allergic bronchopulmonary aspergillosis (abpa), cf-related liver diseases, cf-related diabetes mellitus, and osteoporosis. Additionally, patients wish to become parents themselves. Each of these aspects ask attention of both paediatricians (information and prevention) and medical specialists for adults (treatment). Intensive collaboration between these specialists in cf centers and structured transition of care is of urgent importance.

vorige artikel Aangeboren hartafwijkingen op volwassen leeftijd

volgende artikel Zevende Symposium Neonatale Neurologie

Ratjen F, Doring G. Cystic fibrosis. Lancet. 2003;361(9358): 681-9.CrossRefPubMed

Slieker MG, Uiterwaal CS, Sinaasappel M, et al. Birth prevalence and survival in cystic fibrosis: a national cohort study in the Netherlands. Chest. 2005;128(4):2309-15.CrossRefPubMed

Ent CK van der, Laag J van der, Lammers J-WJ. Protocol. Diagnostiek en behandeling van cystic fibrosis bij kinderen en volwassenen, 2e druk. Utrecht, 2003.

Ratjen F, Döring G. Cystic fibrosis. Lancet. 2003;361 (9358): 681-9.CrossRefPubMed

CF genetic database: www.genet.sickkids.on.ca/cftr.

Ent CK van der, Lammers J-WJ. Cystic fibrosis. In: Kimpen JLL, Boers GHJ, Erkelens DW, Lammers J-WJ, red. Aangeboren aandoeningen. Effecten in het latere leven. Utrecht: Lemma, 2004. p. 87-100.

Rowe SM, Miller S, Sorscher EJ. Mechanisms of disease: Cystic fibrosis. N Engl J Med. 2005;352(19):1992-2001.CrossRefPubMed

De Gracia J, Mata F, Alvarez A, et al. Genotype-phenotype correlation for pulmonary function in cystic fibrosis. Thorax. 2005;60(7):558-63.CrossRefPubMed

Lai HJ, Cheng Y, Cho H, et al. Association between initial disease presentation, lung disease outcomes, and survival in patients with cystic fibrosis. Am J Epidemiol. 2004;159(6): 537-46.CrossRefPubMed

McKone EF, Emerson SS, Edwards KL, Aitken ML. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. Lancet. 2003;361(9370):1671-6.CrossRefPubMed

Koch C, Cuppens H, Rainisio M, et al.; Investigators of the ERCF. European Epidemiologic Registry of Cystic Fibrosis (ERCF): comparison of major disease manifestations between patients with different classes of mutations. Pediatr Pulmonol. 2001;31(1):1-12.CrossRefPubMed

Slieker MG, Sanders EA, Rijkers GT, et al. Disease modifying genes in cystic fibrosis. J Cyst Fibros. 2005;4(Suppl 2):7-13.CrossRefPubMed

Gilljam M, Ellis L, Corey M, et al. Clinical manifestations of cystic fibrosis among patients with diagnosis in adulthood. Chest. 2004;126(4):1215-24.CrossRefPubMed

Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med. 2003;168(8):918-51.CrossRefPubMed

De Almeida MB, Bussamra MH, Rodrigues JC. Allergic bronchopulmonary aspergillosis in paediatric cystic fibrosis patients. Paediatr Respir Rev. 2006;7(1):67-72.CrossRef

Becker JW, Burke W, McDonald G, et al. Prevalence of allergic bronchopulmonary aspergillosis and atopy in adult patients with cystic fibrosis. Chest. 1996;109(6):1536-40.CrossRefPubMed

Knutsen AP, Bellone C, Kauffman H. Immunopathogenesis of allergic bronchopulmonary aspergillosis in cystic fibrosis. J Cyst Fibros. 2002;1(2):76-89.CrossRefPubMed

Mastella G, Rainisio M, Harms HK, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis. A European epidemiological study. Epidemiologic Registry of Cystic Fibrosis. Eur Respir J. 2000;16(3):464-71.CrossRefPubMed

Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis. 2000;30(4):696-709.CrossRefPubMed

Grubman SA, Fang SL, Mulberg AE, et al. Correction of the cystic fibrosis defect by gene complementation in human intrahepatic biliary epithelial cell lines. Gastroenterology. 1995;108:584-92.CrossRefPubMed

Sokol RJ, Durie PR; Cystic Fibrosis Foundation Hepatobiliary Disease Consensus Group. Recommendations for management of liver and biliary tract disease in cystic fibrosis. J Pediatr Gastroenterol Nutr. 1999;28(Suppl 1):S1-13.CrossRefPubMed

Colombo C, Battezzati PM, Crosignani A, et al. Liver disease in cystic fibrosis: A prospective study on incidence, risk factors, and outcome. Hepatology. 2002;36(6):1374-82.PubMed

Ramsey BW, Farrell P, Pencharz PB. Nutritional assessment and management in cystic fibrosis: a consensus report. Am J Clin Nutr. 1992;55:108-16.PubMed

Cotting J, Lentze MJ, Reichen J. Effects of ursodeoxycholic acid treatment on nutrition and liver function in patients with cystic fibrosis and longstanding cholestasis. Gut. 1990;31 (8):918-21.CrossRefPubMed

Goff JS. Esophageal varices, Gastrointest Endosc Clin North Am. 1994;4:747-71.

Mack DR, Traystman MD, Colombo JL, et al. Clinical denouement and mutation analysis of patients with cystic fibrosis undergoing liver transplantation for biliary cirrhosis. J Pediatr. 1995;127:881-7.CrossRefPubMed

Costa M, Potvin S, Berthiaume Y, et al. Diabetes: a major co-morbidity of cystic fibrosis. Diabetes Metab. 2005;31(3 Pt 1):221-32.CrossRefPubMed

Brennan AL, Geddes DM, Gyi KM, Baker EH. Clinical importance of cystic fibrosis-related diabetes. J Cyst Fibros. 2004;3(4):209-22.CrossRefPubMed

Moran A, Hardin D, Rodman D, et al. Diagnosis, screening and management of cystic fibrosis related diabetes mellitus: a consensus conference report. Diabetes Res Clin Pract. 1999;45(1):61-73.CrossRefPubMed

Conway S. Osteoporosis in cystic fibrosis. J Cyst Fibros. 2003;161-2.

Jarzabek K, Zbucka M, Pepinski W, et al. Cystic fibrosis as a cause of infertility. Reprod Biol. 2004;4(2):119-29.PubMed

Palermo GD, Schlegel PN, Hariprashad JJ, et al. Fertilization and pregnancy outcome with intracytoplasmic sperm injection for azoospermic men. Hum Reprod. 1999;14(3):741-8.CrossRefPubMed

McMullen AH, Pasta DJ, Frederick PD, et al. Impact of pregnancy on women with cystic fibrosis. Chest. 2006;129(3):706-11.CrossRef

Goss CH, Rubenfeld GD, Otto K, Aitken ML. The effect of pregnancy on survival in women with cystic fibrosis. Chest. 2003;124(4):1460-8.CrossRefPubMed

Gilljam M, Antoniou M, Shin J, et al. Pregnancy in cystic fibrosis. Fetal and maternal outcome. Chest. 2000;118(1):85-91.CrossRefPubMed

Wahl AK, Rustoen T, Hanestad BR, et al. Living with cystic fibrosis: impact on global quality of life. Heart Lung. 2005;34(5):324-31.CrossRefPubMed

Titel: Cystic fibrosis; een vergrijzend ziektebeeld?
Auteurs: C. K. van der Ent
I. Drubbel
A. M. M. de Vrankrijker
H. G. M. Arets
H. G. M. Heijerman
Publicatiedatum: 01-12-2006
Uitgeverij: Bohn Stafleu van Loghum
Gepubliceerd in: Tijdschrift voor Kindergeneeskunde / Uitgave 6/2006
Print ISSN: 0376-7442
Elektronisch ISSN: 1875-6840
DOI: https://doi.org/10.1007/BF03061646

Andere artikelen Uitgave 6/2006

Opgroeien met een chronische aandoening: levensloop en gevolgen in de jongvolwassenheid

Artikelen

Nazorg Intensive Care Opname (nico): gestructureerde follow-up van fysieke en psychische gevolgen

Artikelen

Vroeggeboorte, intra-uteriene groeiachterstand en lichamelijke ziekten op de volwassen leeftijd; resultaten van 19 jaar pops-follow-up

Artikelen

Gezondheidsproblemen na de behandeling van kinderkanker

Artikelen

Aangeboren hartafwijkingen op volwassen leeftijd

Artikelen

Landelijke richtlijnen voor follow-up van overlevenden van kinderkanker

Artikelen